Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM

JACC Adv. 2026 Jul 1;5(8):102956. doi: 10.1016/j.jacadv.2026.102956. Online ahead of print.ABSTRACTBACKGROUND: Mavacamten, a cardiac myosin inhibitor, has been shown to improve symptoms and reduce left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy (oHCM). However, re

An Unusual Etiology of Bayés' Syndrome: Fabry Disease

Ann Noninvasive Electrocardiol. 2026 Jul;31(4):e70220. doi: 10.1111/anec.70220.ABSTRACTWe present the case of a 72-year-old female with Fabry disease who developed an advanced interatrial conduction block and atrial fibrillation, a condition known as Bayés' syndrome. Fabry disease is an X-linked inh

Subclinical Atrial Fibrillation: Detection, Stroke Risk, and Treatment

Dtsch Arztebl Int. 2026 Oct 2;123(20):arztebl.m2026.0125. doi: 10.3238/arztebl.m2026.0125. Online ahead of print.ABSTRACTBACKGROUND: Clinically evident atrial fibrillation is estimated to affect more than 1.8 million people in Germany. Atrial arrhythmias are increasingly being detected by cardiac de